Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.50 |
| ▸ | PARK7 | Q99497 | 2/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.45 |
| ▸ | EGFR | P00533 | 4/20 | 0.43 |
| ▸ | UBE2N | P61088 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13627959 | 0.88 | ALDH1A1 (0.50) | CHRM5UBE2NTDP1CA1CA2 | |
| SCHEMBL13627936 | 0.88 | TRPA1 (0.62) | TRPA1PARK7CHRM5EGFRALDH1A1 | |
| SCHEMBL13627965 | 0.87 | ALDH1A1 (0.55) | CHRM5CA1CA2CA9CA12 | |
| SCHEMBL13627946 | 0.86 | UBE2N (0.56) | TRPA1PARK7CHRM5EGFRUBE2N | |
| SCHEMBL13910783 | 0.86 | TRPA1 (0.53) | TRPA1PARK7CHRM5EGFRUBE2N | |
| SCHEMBL13627948 | 0.82 | TRPA1 (0.48) | TRPA1PARK7CHRM5EGFRUBE2N | |
| SCHEMBL13910788 | 0.81 | TRPA1 (0.47) | TRPA1PARK7CHRM5EGFRUBE2N | |
| SCHEMBL13627937 | 0.80 | CHRM5 (0.55) | TRPA1PARK7CHRM5EGFRUBE2N | |
| SCHEMBL13627977 | 0.80 | TRPA1 (0.43) | TRPA1PARK7CHRM5CA1CA2 | |
| SCHEMBL13627897 | 0.79 | UBE2N (0.63) | TRPA1EGFRUBE2NTDP1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612065-B2 | Inhibitors of c-JUN N-terminal kinases (JNK) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612065-B2 | Inhibitors of c-JUN N-terminal kinases (JNK) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-03 | — | — | US | disclosed |
| EP-1175399-B1 | INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) | VERTEX PHARMA (US) | 2009-03-11 | — | — | EP | disclosed |
| US-20080033022-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) | SALITURO FRANCESCO G | 2008-02-07 | — | — | US | disclosed |
| US-20080033022-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) | SALITURO FRANCESCO G | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033022-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) | MAP3K1, JUN, MAP3K7 | TRPA1 4561/4885PARK7 1612/4885CHRM5 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.